There aren't too many new CVOTs scheduled to report top-line or full data in the next six months. Most trials listed below are expecting top-line or full data presentation in June or later. There shouldn't be much of any competition for the spotlight from other ongoing trials when BETonMACE top-line data is announced in 1H 2019. 

CAROLINA trial for DPP4 inhibitor linagliptin(top-line anticipated anytime). DPP4 inhibitors have not shown any cardio benefit to date. A parallel linagliptin trial called CARMELINA reported neutral cardio/renal results Q4 2018

PIONEER 6 oral semaglutide GLP1-R agonist full data expected at ADA June 2019 after releasing some impressive partial data last month. Injectable semaglutide previously showed nice cardio benefit in SUSTAIN 6 trial.

REWIND dulaglutide GLP1-R agonist full data expected at ADA June 2019. Significantly reduced 3-point MACE in top-line released 11/5/18. No %RRR reported.

COLCOT trial for Colchicine. Results expected in 2019 (trial completion anticipated betwen March and Sept 2019).

VERTIS-CV trial with ertugliflozin SGLT2 inhibitor. Estimated completion H2 2019.

EVAPORATE trial with Amarin’s Vascepa. Estimated completion H2 2019

STRENGTH trial with Astrazeneca’s EPANOVA. Estimated completion H2 2019.